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Background: Whole exome and genome sequencing (WES/WGS) is now routinely offered as a clinical test by a
growing number of laboratories. As part of the test design process each laboratory must determine the
performance characteristics of the platform, test and informatics pipeline. This report documents one such
characterization of WES/WGS.
Methods: Whole exome and whole genome sequencing was performed on multiple technical replicates of five
reference samples using the Illumina HiSeq 2000/2500. The sequencing data was processed with a GATK-based genome
analysis pipeline to evaluate: intra-run, inter-run, inter-mode, inter-machine and inter-library consistency, concordance
with orthogonal technologies (microarray, Sanger) and sensitivity and accuracy relative to known variant sets.
Results: Concordance to high-density microarrays consistently exceeds 97% (and typically exceeds 99%) and
concordance between sequencing replicates also exceeds 97%, with no observable differences between different flow
cells, runs, machines or modes. Sensitivity relative to high-density microarray variants exceeds 95%. In a
detailed study of a 129 kb region, sensitivity was lower with some validated single-base insertions and deletions “not
called”. Different variants are "not called" in each replicate: of all variants identified in WES data from the NA12878
reference sample 74% of indels and 89% of SNVs were called in all seven replicates, in NA12878 WGS
52% of indels and 88% of SNVs were called in all six replicates. Key sources of non-uniformity are variance in
depth of coverage and artifactual variants resulting from repetitive regions and larger structural variants.
Conclusion: We report a comprehensive performance characterization of WES/WGS that will be relevant to offering
laboratories, consumers of genome sequencing and others interested in the analytical validity of this technology.Background
Whole exome and genome sequencing (WES/WGS) is
now routinely offered as a clinical test by a growing
number of laboratories. WES/WGS is implemented as a
laboratory-developed test that must be fully validated by
the offering laboratory prior to use. This validation effort
“establishes the analytical performance for the clinical
test system … to confirm that the system is suitable for
its intended use” [1], and in this context (next-gener-
ation sequencing) is focused on three inter-related as-
pects: platform, test-specific and informatics pipeline
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article, unless otherwise stated.This report documents one such validation of WES/WGS
for patients without a molecular diagnosis but suspected
constitutional disease mutation(s), with attention to parame-
ters that measure the reproducibility of the testing platform
as well as the informatics pipeline. We performed a focused
evaluation of the analytical performance characteristics of
SNV and small indel (less than 50 bp) detection for a single
workflow across multiple technical replicates. This study
complements the comparisons of different sequencing tech-
nologies [2,3], exome capture techniques [4,5] and informat-
ics pipelines [6,7] that have been reported previously.
The American College of Medical Genetics (ACMG)
has developed clinical laboratory standards for NGS [8],
which specifically address the unique challenges of
WES/WGS. Since WES/WGS is not targeting specific
diseases/genes, the validation effort is not focused on the
specific sequence contexts and variant types associatedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Summary of samples used in validation experiments
with known variants as reported by Coriell
Sample Sex Known variants Note
NA12878 F Heterozygous CYP2C19
c.681G > A (rs4244285)
NA12891 M Homozygous CYP2C19
c.681G > A (rs4244285)
Father to NA12878
NA12892 F N/A Mother to NA12878
NA10080 M Heterozygous PTEN c.781C > T
NA18507 M N/A
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ating end-to-end metrics for high quality sequencing.
Different expectations apply to WES/WGS than tar-
geted panels or single gene testing. For instance, instead
of “sequence-to-completion” for a specific region the
goal is to sensitively and precisely call variants over the
largest percentage of the target region possible, while
also being able to determine and report which bases did
not meet the minimum requirements for successful
variant calling.
The variant calling error rate is determined by many
parameters; setting a single minimum threshold for
confident calls is challenging. We do not attempt to de-
fine a fixed set of quality filters that produce our desired
sensitivity and specificity. Instead we use variant quality
score recalibration (VQSR) [9,10], a statistical technique
for variant filtration that builds a model of “true” vari-
ants using multiple quality parameters and then applies
that model to filter out likely false positive variants.
With VQSR we set desired end-to-end sensitivity and
determine the thresholds for specific quality parameters
directly from the data itself. All performance characteris-
tics were measured in the context of this filtering ap-
proach. VQSR can be combined with separate filters used
to flag for additional investigation genomic regions with
increased likelihood of missed/artifactual variants or geno-
types with increased likelihood of incorrect zygosity.
The scale of WES/WGS makes it prohibitive to evalu-
ate all variants with alternative technologies and the cost
limits the number of samples that can be sequenced as
part of the validation process. We sequenced multiple
technical replicates of five reference samples in a scheme
to extensively but efficiently test intra-run, inter-run,
inter-machine and inter-mode reproducibility. We com-
pared this data to a variety of reference callsets including
SNP arrays, Sanger validation data from targeted NGS
panels offered by our laboratory and publicly available
variant calls to evaluate accuracy, sensitivity and specifi-
city. Ongoing standardization efforts are continually
producing additional and improved reference materials
(RMs) and associated callsets [11]; in this report, for ex-
ample, we use the first release of the “Genomes In a Bot-
tle” (GIAB) variant callset [12]. The rapid evolution of
sequencing technology, informatics tools and RMs make
validation and optimization a continuous process in
which these results represent a particular moment in
time. The process we describe, however, is largely auto-
mated and readily adaptable to new informatics tools
and data resources as they become available.
Methods
Materials
The samples listed in Table 1 were sequenced as mul-
tiple technical replicates according to the schematicsshown in Figures 1 and 2. The samples were chosen to
include a trio (NA12878-NA12891-NA12892) with nu-
merous reference callsets both public and internal, eth-
nic diversity (NA18507) and a sample (NA10080) with a
known disease mutation and internal reference mate-
rials. The replicates were designed to test intra-run
(same run of same machine), inter-run (different run of
same machine), inter-library, inter-machine and inter-
mode (between high-throughput and rapid run modes)
reproducibility. Note that each pair-wise comparison be-
tween replicates may represent more than one of the
above comparisons; tables of comparison type are in-
cluded in the Additional file 1. Replicates are named by
sample/run-machine-slot. DNA was derived from lym-
phoblastoid cell lines from the Coriell Institute for
Medical Research.
Table 2 lists the reference materials used in this
analysis.
Sequencing and variant calling
WES and WGS was performed on a HiSeq 2000/2500
(Illumina, San Diego, CA, USA) with a 100 base-pair
(bp) paired-end protocol. WES samples were barcoded
and pooled with up to three other samples prior to en-
richment for exonic DNA with the Nimblegen SeqCap
EZ Human Exome Library v3.0. The sequencing data is
available via the SRA under BioProjects PRJNA241071
and PRJNA241062.
The genome analysis pipeline (GAP) is based on the
1000 Genomes Project (1000G) data analysis data pipe-
line and is composed from the widely used open source
software projects bwa 0.7.5a [13], Picard 1.96 [14],
GATK 2.7 [9,10], snpEff 3.0 [15], BEDTools 2.16.2 [16]
and custom-developed software. Short-reads are aligned
to a gender- and pseudo-autosomal region (PAR)-masked
build of the hg19 human reference genome using bwa
mem. The GAP implements the “GATK Best Practices”
including indel realignment, de-duplication, and base-
quality score recalibration (BQSR).
Single nucleotide variants (SNVs) and indels were
called jointly with the GATK HaplotypeCaller. Variant
quality score recalibration (VQSR) was used to estimate
Figure 1 Schematic of sequencing runs used in WES validation experiments. Up to 4 samples are multiplexed into a single lane
high-throughput lane. Cross-hatching indicates the same or different library preparations. Run #4 is an Illumina HiSeq 2500 RapidRun,
with each lane treated as a separate replicate. Individual replicates are named as sample/run-machine-slot.
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ant instead of an artifact and set the corresponding vari-
ant filter thresholds. VQSR was used for WGS but not
WES indels, due to an insufficient number of variants to
train the model; fixed filters were used instead. The
PASS threshold for VQSR is set to capture of 99.5%
known true-positives. We observed this threshold to
offer a good compromise between precision and recall;
the impact of changing this threshold can be observed in
the results section in the context of the Genome in a
Bottle (GIAB) reference material. Note that in choosing
a threshold below 100% we set a corresponding mini-
mum false negative rate.
The exome capture targets were expanded with 100 bp
flanks for variant calling. Mean coverage and factions of
bases at different coverage levels were calculated with
the un-flanked intervals; the callable coverage of RefSeq
coding exons was calculated with the flanked intervals.
Array genotyping
Array genotyping was performed on 750 nanograms of
DNA with the Human Omni2.5 BeadChip (Illumina, San
Diego, CA, USA). The hybridized arrays were scanned
using the HiScan system (Illumina, San Diego, CA,
USA) and the genotypes called utilizing the softwareFigure 2 Schematic of sequencing runs used in WGS validation exper
preparations. Individual replicates are named as sample/run-machine-slot.GenomeStudio v1.0 Genotyping Module (Illumina, San
Diego, CA, USA).
Validation statistics
Genotype concordance (concordance) and the related met-
rics, non-reference sensitivity (NRS), non-reference geno-
type concordance (NRC) and precision are computed as
the ratio of solid red elements to blue outline elements
shown in Figure 3 (where “B” is the non-reference allele).
Non-PASSing variants are treated as “no-calls” (./.) and
multi-allelic sites are decomposed into their component
bi-allelic variants. Callsets are joined using strict variant
equality (position, reference and alternate alleles); thus dif-
ferent representations of the same complex variant will not
be recognized as concordant. However, wherever relevant
(ASD panel callset) all variants have been similarly left-
aligned to reduce this effect. And we note that the GIAB
callset was regularized with the same variant caller (GATK
Haplotype Caller). Where relevant, and unless otherwise
specified, all metrics are computed with respect to the tar-
get intervals associated with the callset e.g. the target inter-
vals for any gene panel and the “high-confidence” intervals
supplied alongside the GIAB callset.
All metrics are sensitive to the choice of variants in
the truth and test sets, especially the concordanceiments. Cross-hatching indicates the same or different library
Table 2 Description of reference callsets used in analysis
Dataset Notes (version, target intervals, etc.)
In-house Omni 2.5
Microarray
Described in methods section
1000G Omni 2.5
Microarray
As distributed in GATK Resource Bundle version 2.3




Version 2.17, dated Oct. 17 2013. Most restrictive
“high confidence” intervals excluding simple




129 kilobase targeted clinical sequencing panel of
genes related to austism spectrum disorder (ASD).
Indels are left aligned.
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“test” and “truth” datasets. Including many homozygous
reference genotypes, which can be easier to call, can bias
the concordance metric. The GAP only reports variants
from the reference, minimizing the biasing effect of
homozygous reference calls. Similarly, restricting the
variants in the test set to only very high quality variants
will also bias the concordance statistic, as would restrict-
ing the variants included in the truth set to those readily
called in NGS data. All NGS replicates use the filtering
scheme described previously, and any filters applied to
the reference materials are specified.
Although the SNP microarrays and other callsets are
treated as “truth”, they are not error free. The error rate
for the BeadArray technology is estimated at 0.3% [17],
although the actual error rate will be a function of the
QC strategy employed and as the data shown here suggests,
is actually higher, than that estimate in this context. There
is no “truth” callset when comparing two WES or WGS
callsets that should be identical. In these cases we conduct
the same concordance analysis twice, treating each callset
alternately as both “truth” and “test”. By definition the con-
cordance is symmetric, but differences in NRS, NRC and
Precision will be observed.
Experiments
Table 3 summarizes the different validation experiments
performed. Metrics are computed as described previously.Figure 3 Different genotype concordance metrics. ‘B’ is the alternate all
elements. Non-reference genotype concordance (NRC) is genotype-aware senThe WES and WGS replicates used in different experi-
ments are listed in Table 4, with all replicates used for con-
cordance testing against alternate technologies and curated
variant sets.Results and discussion
Sequencing statistic
Tables 5 and 6 list the coverage statistics for the different
WES and WGS replicates, respectively. The percentage
of RefSeq coding bases considered confidently callable
represents an estimate of the portion of those bases over
which we could confidently call variants. Confidence is
determined by: a minimum of 20-fold coverage and no
more than 10% MAPQ0 (ambiguously mapped) reads.
This estimate is intended to be conservative (the coverage
threshold is set at the upper end of the range suggested in
the guidelines [8]) however, we may still fail to call vari-
ants in regions that are considered “confidently callable”.Microarrays
Figure 4 shows the concordance, NRS and NRC rela-
tive to three different SNP microarray genotypes (the
“In-house Omni 2.5 Microarray”, “1000G Omni 2.5
Microarray” and “Hapmap” reference callsets). The con-
cordance exceeds 97% (98.5% for more filtered 1000G
array), with the NRS exceeding 92.5% (95% excluding
HapMap). These results are consistent with the con-
cordance rates listed in the guidelines [8]. The observed
NRS is lower than the sensitivity set in VQSR (99.5%),
even though the same datasets (1000G Omni 2.5 and
Hapmap 3.3 genotypes) are used in that training process,
showing the impact of insufficient coverage and various
error processes, e.g. low complexity and structural vari-
ants, on end-to-end sensitivity. For example, more missed
variants are located on the hyper-variable MHC region of
chromosome 6, than any other chromosome region. The
NRS increases 2-3% if we restrict the concordance analysis
to those variants in regions identified as callable per the
requirements specified above.
The stratification in NRS and NRC reflects the different
technologies and QC procedures of the array data sources.
More filtering was applied to the 1000G Omni 2.5 genotypesele. Each metric is calculated as the ratio of red elements to blue-outline
sitivity/recall.
Figure 4 WES (A) and WGS (B) genotype concordance (concordance), non-reference sensitivity (NRS) and non-reference concordance
(NRC) relative to three different SNP microarray genotypes: 1) an Illumina Omni2.5 genotype performed in-house, 2) an Omni2.5 geno-
type performed as part of the 1000 Genomes project, and 3) Hapmap 3.3 genotype. Not all genotypes are available for all samples. Only
those SNPs within the exome capture targets are considered for WES concordance. The GAP does not report non-variant sites, so homozygous
reference calls are not considered in the concordance evaluation.
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an indel, than the Omni 2.5 genotyping performed in-house,
which has no specific QC filters applied. We expect higher
NRS and NRC relative to the 1000G arrays as a result.
Unlike the Omni arrays, the HapMap dataset was lifted to
hg19 from hg18/GRCh36. The resulting mapping errors
could introduce artifactual variants that bias sensitivity.
Genome in a bottle
The mean concordance, NRS and NRC relative to the
GIAB variant callset (with full range in brackets), restricted
to variants within the GIAB high-confidence regions, are
99.0% [98.2,99.6], 96.1% [95.4,96.5] and 95.1% [94.5,95.8],
respectively, for WES and 99.7% [99.6,99.7], 94.2%Table 3 Summary of validation experiments performed
Experiment Action
Concordance with SNP Array Measure concordance






by in-house Sanger as
Intra-run reproducibility Measure concordance
A) Different sample pr
B) The same sample p
Inter-run reproducibility Measure concordance
A) The same sample p
B) Different sample pre
Inter-machine reproducibility Measure concordance
machines of the same
Inter-mode reproducibility Measure concordance[93.0,95.4] and 93.9% [92.7,95.1], respectively, for WGS. All
metrics are improved compared to using the microarrays
as the truth callset, as would be expected. The GIAB callset
is produced from similar NGS datasets, using a similar
analysis pipeline, and the analysis was restricted to the
GIAB high-confidence regions. If we further restrict to
those variants in regions identified in each replicate as call-
able (and thus eliminate low coverage regions in each sam-
ple), the mean NRS increases to 98.9% and 95.0% for WES
and WGS respectively, with the NRS improving for all rep-
licates. Approximately 90% of those WGS variants that
would be considered FNs relative to the GIAB callset are
called in our data, but marked as non-PASSing. MQ is
identified as the “culprit” by VQSR in the majority of thosewith high-density SNP arrays
with Genome In A Bottle (GIAB) NA12878 callset
with calls from a targeted NGS panel (all calls previously validated either
says or the presence of the variant in the sample in Hapmap, 1000G, etc.)
for the same sample sequenced in the same run with:
eparations across the same flow cell, or
reparation across different flow cells
for the same sample on the same machine with:
reparation different runs, or
paration across different runs
for the same sample with the same sample preparation on different
model in the same run cycle
between high-throughput and rapid run Illumina modes
Table 4 WES and WGS samples used in different concordance experiments
Experiment WES comparison sets WGS comparison sets
Intra-run reproducibility NA12878: r1-1-1 vs. r1-1-2 NA12878: r1-1-1 vs. r1-1-3
NA18507: r2-1-2 vs. r2-1-3 NA18507: r2-1-3 vs. r2-1-4
Inter-run reproducibility NA18507: r2-1-2 vs. r3-1-2 NA18507: r2-1-3 vs. r3-1-3
NA18507: r2-1-3 vs. r3-1-2 NA18507: r2-1-4 vs. r3-1-3
NA12878: r1-1-1 vs. r2-1-1 vs. r3-1-1 NA12878: r1-1-1 vs. r2-1-1 vs. r3-1-1
NA12878: r2-2-1 vs. r3-2-1
Inter-machine reproducibility NA12878: r3-1-1 vs. r3-2-1 NA12878: r3-1-1 vs. r3-2-1
NA12878: r4-1-1 vs. r4-2-1 NA12878: r2-1-1 vs. r2-2-1
NA18507: r4-1-2 vs. r4-2-2
Inter-mode reproducibility NA12878, NA18507, NA12891, NA12892 r4-*-* versus all others N/A
Linderman et al. BMC Medical Genomics 2014, 7:20 Page 6 of 11
http://www.biomedcentral.com/1755-8794/7/20filtered variants. We note that MQ is no longer a recom-
mended VQSR annotation, a change we would expect to
improve VQSR performance.
To investigate the impact of our filtering approach on
analytical performance, we plot the precision-recall (PR)
curves for WES/WGS SNVs and indels relative to the allTable 5 Summary of WES coverage statistics
Replicate Mean % Bases > =1X % Bases > =10X %
NA12878
r1-1-1 57.4 96.8 93.6 8
r1-1-2 57.4 96.8 93.6 8
r2-1-1 66.8 96.2 92.0 8
r3-1-1 81.8 96.7 93.6 9
r3-2-1 74.5 96.7 93.6 9
r4-1-1 83.7 96.7 93.7 9
r4-2-1 73.6 96.6 93.2 8
NA12891
r3-1-3 70.9 96.5 92.4 8
r4-1-3 70.8 96.6 92.5 8
r4-2-3 60.9 96.3 91.4 8
NA12892
r3-1-4 70.7 96.5 92.7 8
r4-1-4 71.4 96.6 92.8 8
r4-2-4 61.7 96.4 91.9 8
NA18507
r2-1-2 66.4 96.4 92.1 8
r2-1-3 92.2 96.7 93.6 9
r3-1-2 81.2 96.7 93.2 8
r4-1-2 82.8 96.7 93.3 8
r4-2-2 71.5 96.5 92.6 8
NA10080
r2-1-4 60.7 96.4 92.1 8
Percent RefSeq Coding Bases Callable reports the percentage of all RefSeq coding e
callable. The baseline value for the capture targets is 95.5%.and just the high-confidence GIAB callsets in Figure 5.
The points show actual PR at the PASS threshold. We
observe that the filters are effectively set at the inflection
point where relaxing the threshold results more false
positives (FPs) than true positives (TPs). We note that




















xons bases (as downloaded from the UCSC Genome Browser) considered
Table 6 Summary of WGS coverage statistics
Replicate Mean % Bases > =1X % Bases > =10X % Bases > =20X % Bases > =30X % Coding bases callable
NA12878
r1-1-1 51.0 95.4 94.9 94.3 93.1 91.8
r1-1-3 49.8 95.4 94.9 94.3 93.1 91.9
r2-1-1 36.5 95.4 94.7 93.5 86.9 91.6
r2-2-1 34.6 95.4 94.7 93.2 82.9 91.2
r3-1-1 49.9 95.5 95.0 94.5 93.5 91.9
r3-2-1 39.8 95.5 94.8 93.9 89.4 91.0
NA12891
r3-1-2 42.7 96.8 96.1 94.3 88.7 91.2
NA12892
r3-1-4 45.1 95.2 90.8 86.6 81.3 90.9
NA18507
r2-1-3 30.0 96.8 95.7 89.4 65.8 87.3
r2-1-4 35.8 96.8 96.0 92.3 83.4 90.2
r3-1-3 51.7 96.9 96.3 95.4 91.6 91.6
NA10080
r2-1-2 35.1 96.9 96.1 92.0 81.7 89
Percent RefSeq Coding Bases Callable reports the percentage of all RefSeq coding exons bases (as downloaded from the UCSC Genome Browser)
considered callable.
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TPs result from relaxed filtering. In situations, such as
clinical workflows, where FNs are very problematic and
FPs less so, treating all variants in the high-confidence
region as PASSing might be a good tradeoff.
Targeted gene panel
Table 7 lists the site-level sensitivity (NRS), specificity and
genotype-level NRC relative to Sanger validated and or Hap-
Map, 1000G and NIST genotypes in 129 kilobases (kb) ofFigure 5 Precision vs. non-reference concordance (NRC) for WES (A) a
of VQSR VQSLoD score relative to GIAB high confidence and all varia
the standard deviation. Points show the PR at the VQSR PASSing threshold
variants (both PASS and not-PASS).target from a clinical multigene panel (the ASD Panel call-
set). Not all variants were validated during panel design and
testing, e.g. intronic variants or the Sanger results are incon-
clusive so we cannot always determine if a WES variant is a
false positive (FP). Thus we report a mix of FPs and “excess”
positives, variants discovered with NGS that were not
Sanger confirmed or not conclusively reported elsewhere.
Table 8 lists the false negative (FN) variants for NA12878
in the panel’s target regions. The most common FN, 3/6
WES FNs and 9/11 WGS FNs, is a single-base deletion innd WGS (B) SNVs (solid line) and Indels (dashed line) as a function
nt sets. Thick line is mean across all replicates; shaded region shows
. VQSR is not applied in WES indels; points show PR for PASSing and all
Table 7 Site-level sensitivity (NRS), specificity and genotype-level NRC relative to Sanger validated and or Hapmap or
1000G-reported variants in 129 Kb of target from a clinical gene panel (the ASD panel callset)
Replicate Variants TP FP/EP FN TN Diff. Alleles Sensitivity (NRS) NRC
NA12878 Exome
r1-1-1 48 40 5 3 0 0 93.0% 81.4%
r1-1-2 46 40 2 3 1 0 93.0% 83.7%
r2-1-1 45 37 1 6 1 0 86.0% 74.4%
r3-1-1 44 40 0 3 1 0 93.0% 83.7%
r3-2-1 44 40 0 3 1 0 93.0% 83.7%
r4-1-1 44 39 0 4 1 0 90.7% 79.1%
r4-2-1 44 39 0 4 1 0 90.7% 81.4%
NA12878 Genome
r1-1-1 64 54 1 8 1 1 87.3% 81.0%
r1-1-3 74 53 11 9 1 1 85.7% 79.4%
r2-1-1 73 53 10 9 1 1 85.7% 77.8%
r2-2-1 73 54 10 8 1 1 87.3% 81.0%
r3-1-1 71 55 8 7 1 1 88.9% 81.0%
r3-2-1 64 52 1 10 1 1 84.1% 74.6%
Not all variants in this interval were validated, e.g. intronic variants, so we cannot conclusively determine if a variant is a false positive. Instead we report “excess
positives”, variants discovered in the NGS replicates that were not Sanger confirmed or conclusively reported elsewhere.
Table 8 False negative variants in NA12878 relative to the ASD panel callset




chr10:89720907 T>G T/G 4/7 No Called, but filtered in some replicates for MQ
chr12:2614070 G>T G/T 6/7 Yes (silent) Called, but filtered in one replicate
chrX:15863648 GA>G GA/G 0/7 No Not called in any replicate; 10 bp homopolymer
chrX:135115669 GA>G GA/G 0/7 No Called, but filtered in two replicates; 11 bp homopolymer
chrX:152954025 A>G G/G 6/7 Yes (UTR) Low depth region
chrX:153287314 TG>T TG/T 0/7 Yes (UTR) Called, but filtered in all replicates for QD; 10 bp homopolymer
Genome
chr5:176639217 TA>T TA/T 0/6 No Not called in any replicate; 13 bp homopolymer
chr7:146805220 AT>A AT/A 0/6 No Not called in any replicate; 11 bp homopolymer
chr10:89720633 CT>C CT/C 0/6 No Not called in any replicate; 15 bp homopolymer
chr10:89720907 T>G T/G 0/6 No Called, but filtered in all replicates
chr11:70348852 G>CG CG/CG 0/6 No Called, but as heterozygous in all replicates; inside 12 bp homopolymer
chrX:15863648 GA>G GA/G 0/6 No Not called in any replicate; 10 bp homopolymer
chrX:132888207 TA>T TA/T 3/6 No Not called in three replicates; 16 bp homopolymer
chrX:135067675 G>C G/C 5/6 Yes (missense) Not called in one replicate
chrX:135115669 GA>G GA/G 1/6 No Called in one replicate; 11 bp homopolymer
chrX:153287314 TG>T TG/T 1/6 Yes (UTR) Called in one replicate; 10 bp homopolymer
chrX:153357614 TA>T TA/T 1/6 No Called in one replicate; 13 bp homopolymer
Most common error mode is single base deletions in homopolymer regions. Each variant is annotated as to whether it would be further reviewed in
interpretations workflow (Yes) or automatically filtered out from further consideration (No).
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instrument’s error rate increases in homopolymer regions,
making it more difficult to detect indels in these contexts
[19,20]. As such, these FNs are not unexpected. For these
particular variants, the deletion is typically detected in a
small fraction of the reads (<10%), too few to accurately
call the heterozygous deletion. A pileup for a representative
example is included in the Additional file 1. Increasing the
read depth does reduce the number FNs that result from
variation in filtering, but not the missed deletions. Most of
the single-base deletions are also not reliably called in
high-depth (over 250-fold) targeted sequencing. As in the
WES/WGS, the deletions are detected in only a small frac-
tion of the reads.
The FN variants in Table 8 impact the analytical sensitivity,
but may not necessarily impact clinical sensitivity. The vari-
ants chrX:15863648GA>G and chrX:135115669GA>G, for
example, occur in homopolymer intronic regions out-
side the invariant splice site, and thus are unlikely to result
in a change in protein functionality and would not be con-
sidered for in-depth review. We annotated each variant in
Table 8 as to whether it would be reviewed in a variant in-
terpretation workflow focused exclusively on known
disease mutations or exonic/splice variants; 50% or
more variants would be filtered out automatically and
not reviewed further.
To evaluate our sensitivity, more generally, for the
subset of variants more likely to be pathogenic, we
tested the sensitivity relative to the high-confidence loss-
of-function (LoF) mutations in NA12878 reported in
MacArthur et al.’s study of LoF variants in the 1000
Genomes cohort [21]. We detected 56–57 of 61 variants
in the WES replicates (sensitivity of 92-93%) and 68–70Figure 6 WES (A) and WGS (B) genotype concordance (concordance),
(NRC) for all pairwise comparisons of the technical replicates, differen
machine and inter-mode. Those comparisons marked as “other” fit into m
treated as both “truth” and “test”.of 73 variants in the WGS replicates (sensitivity of
93-96%). As with other NGS-derived callsets, directly
extrapolating sensitivity from this dataset is likely an
overestimate (because the dataset may not include vari-
ant types/regions that are difficult to sequence).
In those NA12878 replicates with multiple FPs relative
to the ASD panel callset, the majority are artifacts created
by two larger structural variants in the introns of SHANK3
detected manually during the review of discordant calls.
Although the individual variants are PASSing, manual re-
view of the pileup (Additional file 1) immediately shows
these variants to be artifacts of the larger variant. The
same variant caller can produce very different calls for dif-
ferent sequencing replicates, even with similar coverage,
in and around these structural variants and repeat regions.
The differences are not in the filtering, but in which vari-
ants the caller emits. These artifactual variants manifest as
FPs, and will reduce the NRS and NRC, but not the
concordance, when using NGS datasets as truth. The
remaining FPs are non-recurrent errors in 1–2 replicates.
Technical replicates
Figure 6 shows the concordance, NRS and NRC for all
pairwise comparisons of NA12878 and NA18507 repli-
cates, marked as the kind of comparison, i.e. intra-run,
inter-run, inter-machine, inter-mode, inter-library, where
appropriate. Many comparisons are of more than one
kind; those without a clear primary specific classification
are marked as “other”. Visual inspection does not indi-
cate any clear relationship between comparison kind and
concordance. To quantitatively assess the contribution
of these different kinds of comparisons to the concord-
ance, we performed a multiple linear regression analysisnon-reference sensitivity (NRS) and non-reference concordance
tiated by the kind of comparison: intra-run, inter-run, inter-
ultiple categories, including inter-library. Each replicate is alternately
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and the sample ID as a binary control variable on con-
cordance for all NA12878 and NA18507 replicate pairs.
A separate regression analysis was performed for WES
(31 pairs) and WGS (18 pairs). WES did not significantly
differ from the null model (sample covariate alone) at a
threshold of 0.05, while WGS did significantly differ (P
= 0.016). We further analyzed each WGS comparison
type individually. The only comparison kind to be re-
ported as significant (P = .0044) at a threshold of 0.0125
(Bonferroni corrected for 4 tests) was WGS inter-library;
the coefficient estimate translates to a reduction in
concordance of 0.0006, i.e. from 99% to 98.94%. The
regression analysis is described in more detail in the
Additional file 1.
Table 9 lists the fractions of different types of vari-
ants uniformly called in different fractions of repli-
cates. Of all variants identified in WES data from the
NA12878 reference sample 74% of indels and 89% of
SNVs were called PASSing or not PASSing in all seven
replicates. In NA12878 WGS 52% of indels and 88% of
SNVs were uniformly called in all six replicates. The
non-uniformity is only partially a result of variation
in depth of coverage. Restricting the analysis to the
“squared-off” intersection of confidently callable re-
gions across all replicates increases the percentage of
SNVs in all replicates by approximately 2–4 and indels
by 7–10. Further restricting the analysis to the GIAB
high-confidence regions further increases the percent-
ages of variants uniformly called across all replicates
by a similar amount: 89.5% of indels and 97.9% of
SNVs are uniformly called in the NA12782 WES repli-
cates, and 71.0% of indels and 93.2% of SNVs in the
WGS replicates. The number of uniquely observed
variants, i.e. variants called in only one replicate, is in
the range [118–252] and [29395–54746] for NA12878Table 9 Percentage of variants, by type, that are called
identically at the site level across different subsets of
replicates
NA12878 WES 1/7 2/7 3/7 4/7 5/7 6/7 7/7
SNV 3.20 1.37 1.18 1.28 1.42 2.69 88.85
Indel 10.25 4.60 2.62 2.33 2.51 3.71 73.99
NA18507 WES 1/5 2/5 3/5 4/5 5/5
SNV 2.87 1.60 1.47 2.62 91.43
Indel 7.61 3.57 2.96 3.70 82.17
NA12878 WGS 1/6 2/6 3/6 4/6 5/6 6/6
SNV 3.40 1.76 1.52 1.79 3.69 87.80
Indel 20.20 9.89 6.11 5.17 7.07 51.60
NA18507 WGS 1/3 2/3 3/3
SNV 2.61 2.93 94.46
Indel 20.01 13.10 66.89WES and WGS, respectively, and [182–335] and
[66342–104224] for NA18507 WES and WGS
respectively.
Conclusions
We evaluated the intra-run, inter-run, inter-mode and
inter-machine reproducibility, concordance with orthogonal
technologies (microarray, Sanger) and sensitivity relative to
known variant sets (GIAB, MacArthur et al.) for both WES
and WGS across multiple technical replicates of five differ-
ent reference samples. These analyses were performed as
part of the validation of WES/WGS as a clinical test in our
laboratory and as a result focus on a single informatics
pipeline and exome capture technology. However since
both technologies are widely used or are generally reflective
of alternative approaches, the results presented here should
be broadly relevant to anyone interested in the performance
characteristics of WES/WGS.
The state of reference callsets is changing rapidly, with
GIAB and GeT-RM being just two examples of newly
available callsets for NA12878. Those and similar re-
sources will continue to improve and expand, and there-
fore any analysis using such resources represents a
snapshot of a particular moment in time. The different
sensitivities observed for different kinds of callsets
(microarray, NGS-derived datasets like GIAB and Sanger
sequencing) shows the continued challenges in genotyp-
ing different kinds of variation as well as the continuing
challenges in building high-quality, comprehensive refer-
ence callsets The comparisons with Sanger data, for in-
stance, show that indels in homopolymer regions are
under-detected, while the comparisons to NGS-derived
datasets, like GIAB, show how the structural variants
and repeat regions can be interpreted very differently by
different variant callers, even when restricting to high-
coverage, high-confidence regions.
At the time of this report, there are no absolute stan-
dards for the analytical performance characteristics for
WES/WGS but the results presented here fall within the
ACMG suggested ranges [8]. By the nature of WES/
WGS, most of the reported analyses are focused on ana-
lytical performance characteristics that are independent
of any particular clinical scenario. We have successfully
used the documented workflow, however, to make a mo-
lecular diagnosis in 4 of 8 pilot clinical WES cases, indi-
cating that its performance translates to a useful clinical
sensitivity that is on par with that reported by other la-
boratories [22] and at the suggested 50% threshold for
cost effectiveness [23]. The difference between the clin-
ical sensitivity and the much higher analytical sensitivity
for SNVs and small indels reported here reinforces the
need to continue to improve our sequencing, variant
calling and variant interpretation technologies (even a
1% false negative rate in WES/WGS translates into many
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other variant types, e.g. CNVs, which contribute to dis-
ease burden.
Additional file
Additional file 1: Supplemental methods, figures and tables.
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